All Articles

With record growth and a fortified cash position, ElevateBio combines AI-driven discovery and industrial-scale manufacturing to power the gene therapy boom.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

Keystone doubles down on AI advisory with Audax Private Equity's backing, spinning off its supply chain software unit into a new powerhouse, Keystone AI.

With nearly $30M in new funding, fintech firm Obita is building a blockchain-based network to tackle the high costs and delays of global B2B transactions.

The pet franchise doubled its stores in 3 years, achieving $150M in sales. Its rapid rise reflects a booming market and a new competitive landscape.

A new alliance between fintech innovators K1x and Juno promises to automate the most dreaded part of tax season, freeing CPAs from manual data entry.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

The medtech firm's preliminary results show a Q4 revenue uptick but miss yearly estimates, signaling a stabilizing but cautious path forward for 2026.

Otis secures a major TfL contract to upgrade 172 escalators, blending a century of history with future-ready tech for a smarter, more reliable commute.

A looming 10-million-ton copper deficit threatens to derail the AI revolution and the green energy transition, sparking a new era of geopolitical competition.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

With gold hitting record highs, investors are keenly awaiting Kinross's update on three critical US projects that could define its production for a decade.

Cybersecurity firm Corero appoints an award-winning leader to supercharge its partner program, signaling a major push in the competitive DDoS defense market.

The special mission aviation provider completes a buyout of Bain Capital, consolidating NTC Group's ownership and securing new capital to expand its services.

With a 432% share price jump and billions in financing lined up, Troilus Gold's Quebec project is becoming a cornerstone of North America's critical minerals.

Calgary-based Horizon Petroleum faces a Management Cease Trade Order over delayed financial filings, raising questions about its European operations.

AI data platform Protege raises its Series A to $65M, tackling the critical data bottleneck with an ethical, licensing-first model for real-world data.

Eurythmics legend Dave Stewart launches a new venture builder to give artists control over their IP and revenue. But can this "creativity-first" model work?